Skip to main content

Advertisement

Articles

Page 1 of 25

  1. Despite the impressive complete remission (CR) induced by CD19 CAR-T cell therapy in B-ALL, the high rate of complete responses is sometimes limited by the emergence of CD19-negative leukemia. Bispecific CAR-m...

    Authors: Hanren Dai, Zhiqiang Wu, Hejin Jia, Chuan Tong, Yelei Guo, Dongdong Ti, Xiao Han, Yang Liu, Wenying Zhang, Chunmeng Wang, Yajing Zhang, Meixia Chen, Qingming Yang, Yao Wang and Weidong Han

    Citation: Journal of Hematology & Oncology 2020 13:30

    Content type: Rapid communication

    Published on:

  2. Cancer immunotherapy has reached a critical point, now that immune checkpoint inhibitors and two CAR-T products have received market approval in treating 16 types of cancers and 1 tissue-agnostic cancer indica...

    Authors: Chongxian Pan, Hongtao Liu, Elizabeth Robins, Wenru Song, Delong Liu, Zihai Li and Lei Zheng

    Citation: Journal of Hematology & Oncology 2020 13:29

    Content type: Review

    Published on:

  3. Immunotherapy with immune checkpoint inhibitors (ICIs) for solid tumors had significantly improved overall survival. This type of therapy is still not available for acute myeloid leukemia (AML). One major issu...

    Authors: Cunte Chen, Chaofeng Liang, Shunqing Wang, Chi Leong Chio, Yuping Zhang, Chengwu Zeng, Shaohua Chen, Caixia Wang and Yangqiu Li

    Citation: Journal of Hematology & Oncology 2020 13:28

    Content type: Letter to the Editor

    Published on:

  4. Previous reports suggest a benefit associated with haploidentical donor transplantation (HIDT) compared to matched sibling donor transplantation (MSDT) in certain contexts, and the choice of optimal candidates...

    Authors: Ying-Jun Chang, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Huan Chen, Yu-Hong Chen, Feng-Rong Wang, Wei-Han, Yu-Qian Sun, Chen-Hua Yan, Fei-Fei Tang, Xiao-Dong Mo, Yan-Rong Liu, Kai-Yan Liu and Xiao-Jun Huang

    Citation: Journal of Hematology & Oncology 2020 13:27

    Content type: Research

    Published on:

  5. Protein-protein interactions (PPIs) are central to a variety of biological processes, and their dysfunction is implicated in the pathogenesis of a range of human diseases, including cancer. Hence, the inhibiti...

    Authors: Sha-Sha Cheng, Guan-Jun Yang, Wanhe Wang, Chung-Hang Leung and Dik-Lung Ma

    Citation: Journal of Hematology & Oncology 2020 13:26

    Content type: Review

    Published on:

  6. During malignant transformation, accumulated somatic mutations endow cancer cells with increased invasiveness and immunogenicity. Under selective pressure, these highly immunogenic cancer cells develop multipl...

    Authors: Ming Yi, Linping Xu, Ying Jiao, Suxia Luo, Anping Li and Kongming Wu

    Citation: Journal of Hematology & Oncology 2020 13:25

    Content type: Review

    Published on:

  7. Aerobic glycolysis is a hallmark of metabolic reprogramming that contributes to tumor progression. However, the mechanisms regulating expression of glycolytic genes in neuroblastoma (NB), the most common extra...

    Authors: Huajie Song, Dan Li, Xiaojing Wang, Erhu Fang, Feng Yang, Anpei Hu, Jianqun Wang, Yanhua Guo, Yang Liu, Hongjun Li, Yajun Chen, Kai Huang, Liduan Zheng and Qiangsong Tong

    Citation: Journal of Hematology & Oncology 2020 13:24

    Content type: Research

    Published on:

  8. The original article [1] contains an error in Fig. 5b whereby two panels have been mistakenly duplicated. The correct version of Fig. 5b can be viewed ahead alongside the rest of Fig. 5.

    Authors: Shaoquan Zheng, Lu Yang, Yutian Zou, Jie-ying Liang, Peng Liu, Guanfeng Gao, Anli Yang, Hailin Tang and Xiaoming Xie

    Citation: Journal of Hematology & Oncology 2020 13:23

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2020 13:17

  9. Methylation of RNA and DNA, notably in the forms of N6-methyladenosine (m6A) and 5-methylcytosine (5mC) respectively, plays crucial roles in diverse biological processes. Currently, there is a lack of knowledge r...

    Authors: Yu-Tong Chen, Jia-Yi Shen, Dong-Ping Chen, Chen-Fei Wu, Rui Guo, Pan-Pan Zhang, Jia-Wei Lv, Wen-Fei Li, Zi-Xian Wang and Yu-Pei Chen

    Citation: Journal of Hematology & Oncology 2020 13:22

    Content type: Letter to the Editor

    Published on:

  10. Mantle cell lymphoma (MCL) is a B cell malignancy that can be aggressive and with a poor prognosis; the clinical course is heterogeneous. The epidemiology of MCL in Asia is not well documented but appears to c...

    Authors: Dok Hyun Yoon, Junning Cao, Tsai-Yun Chen, Koji Izutsu, Seok Jin Kim, Yok Lam Kwong, Tong Yu Lin, Lim Soon Thye, Bing Xu, Deok Hwan Yang and Won Seog Kim

    Citation: Journal of Hematology & Oncology 2020 13:21

    Content type: Review

    Published on:

  12. Distinct from classical tumor angiogenesis, vasculogenic mimicry (VM) provides a blood supply for tumor cells independent of endothelial cells. VM has two distinct types, namely tubular type and patterned matr...

    Authors: Qingxi Luo, Jun Wang, Wenyuan Zhao, Zhenzi Peng, Xianyu Liu, Bin Li, Heng Zhang, Bin Shan, Chunfang Zhang and Chaojun Duan

    Citation: Journal of Hematology & Oncology 2020 13:19

    Content type: Review

    Published on:

  13. Compared with HLA-matched sibling donor (MSD) transplant, the outcomes of haploidentical donor (HID) transplant for refractory acute leukemia need to be further explored. In this study, we compared the outcome...

    Authors: Sijian Yu, Fen Huang, Zhiping Fan, Li Xuan, Danian Nie, Yajing Xu, Ting Yang, Shunqing Wang, Zujun Jiang, Na Xu, Ren Lin, Jieyu Ye, Dongjun Lin, Jing Sun, Xiaojun Huang, Yu Wang…

    Citation: Journal of Hematology & Oncology 2020 13:18

    Content type: Short report

    Published on:

  14. Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer with highly invasive ability and metastatic nature to the lymph nodes. Long non-coding RNAs (lncRNAs) have been widely explor...

    Authors: Shaoquan Zheng, Lu Yang, Yutian Zou, Jie-ying Liang, Peng Liu, Guanfeng Gao, Anli Yang, Hailin Tang and Xiaoming Xie

    Citation: Journal of Hematology & Oncology 2020 13:17

    Content type: Research

    Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2020 13:23

  15. NoncoRNA (http://​www.​ncdtcdb.​cn:​8080/​NoncoRNA/​) is a manually curated database of experimentally supported non-coding RNAs (ncRNAs) and drug target associations that aim to potentially provide a high-quality data...

    Authors: Lulu Li, Pengfei Wu, Zhenyu Wang, Xiangqi Meng, Caijun Zha, Ziwei Li, Tengfei Qi, Yangong Zhang, Bo Han, Shupeng Li, Chuanlu Jiang, Zheng Zhao and Jinquan Cai

    Citation: Journal of Hematology & Oncology 2020 13:15

    Content type: Letter to the Editor

    Published on:

  16. Metaplastic breast cancer (MBC) is a rare form of breast cancer characterized by an aggressive clinical presentation, with a poor response to standard chemotherapy. MBCs are typically triple-negative breast ca...

    Authors: F. Coussy, R. El Botty, M. Lavigne, C. Gu, L. Fuhrmann, A. Briaux, L. de Koning, A. Dahmani, E. Montaudon, L. Morisset, L. Huguet, L. Sourd, P. Painsec, S. Chateau-Joubert, T. Larcher, S. Vacher…

    Citation: Journal of Hematology & Oncology 2020 13:13

    Content type: Short report

    Published on:

  17. MicroRNA-612 (miR-612) has been proven to suppress EMT, stemness, and tumor metastasis of hepatocellular carcinoma (HCC) via PI3K/AKT2 and Sp1/Nanog signaling. However, its biological roles on HCC progression ...

    Authors: Yang Liu, Li-Li Lu, Duo Wen, Dong-Li Liu, Li-Li Dong, Dong-Mei Gao, Xin-Yu Bian, Jian Zhou, Jia Fan and Wei-Zhong Wu

    Citation: Journal of Hematology & Oncology 2020 13:12

    Content type: Research

    Published on:

  18. Aberrant AKT activation contributes to cancer stem cell (CSC) traits in hepatocellular carcinoma (HCC). We previously reported that CD73 activated AKT signaling via the Rap1/P110β cascade. Here, we further exp...

    Authors: Xiao-Lu Ma, Bo Hu, Wei-Guo Tang, Su-Hong Xie, Ning Ren, Lin Guo and Ren-Quan Lu

    Citation: Journal of Hematology & Oncology 2020 13:11

    Content type: Research

    Published on:

  19. Lung cancer (LC) is the leading cause of cancer-related death worldwide due to its late diagnosis and poor outcomes. As has been found for other types of tumors, there is increasing evidence that myeloid-deriv...

    Authors: Zhenzhen Yang, Jiacheng Guo, Lanling Weng, Wenxue Tang, Shuiling Jin and Wang Ma

    Citation: Journal of Hematology & Oncology 2020 13:10

    Content type: Review

    Published on:

  20. PARP inhibitors have been the most promising target drugs with widely proven benefits among ovarian cancer patients. Although platinum-response, HR-related genes, or HRD genomic scar detection are acceptably u...

    Authors: Chenggong Sun, Wenyu Cao, Chunping Qiu, Chengcheng Li, Samina Dongol, Zhiwei Zhang, Ruifen Dong, Kun Song, Xingsheng Yang, Qing Zhang and Beihua Kong

    Citation: Journal of Hematology & Oncology 2020 13:9

    Content type: Research

    Published on:

  21. Acute myeloid leukemia (AML) is the most common type of adult leukemia. Several studies have demonstrated that oncogenesis in AML is enhanced by kinase signaling pathways such as Src family kinases (SFK) inclu...

    Authors: Ola A. Elgamal, Abeera Mehmood, Jae Yoon Jeon, Bridget Carmichael, Amy Lehman, Shelley J. Orwick, Jean Truxall, Virginia M. Goettl, Ronni Wasmuth, Minh Tran, Shaneice Mitchell, Rosa Lapalombella, Sudharshan Eathiraj, Brian Schwartz, Kimberly Stegmaier, Sharyn D. Baker…

    Citation: Journal of Hematology & Oncology 2020 13:8

    Content type: Research

    Published on:

  22. Long noncoding RNAs (lncRNAs) are known to regulate tumorigenesis and cancer progression, but their contributions to non-small-cell lung cancer (NSCLC) metastasis remain poorly understood. Our previous and oth...

    Authors: Zhenyao Chen, Xin Chen, Binbin Lu, Yu Gu, Qinnan Chen, Tianyao Lei, Fengqi Nie, Jingyao Gu, Jiali Huang, Chenchen Wei, Ming Sun and Zhaoxia Wang

    Citation: Journal of Hematology & Oncology 2020 13:7

    Content type: Research

    Published on:

  23. BPI-9016M is a novel small-molecule inhibitor that simultaneously targets both c-Met and AXL tyrosine kinases. This phase I study aimed to determine the maximum tolerated dose (MTD), safety, pharmacokinetics, ...

    Authors: Xingsheng Hu, Xin Zheng, Sheng Yang, Lin Wang, Xuezhi Hao, Xinge Cui, Lieming Ding, Li Mao, Pei Hu and Yuankai Shi

    Citation: Journal of Hematology & Oncology 2020 13:6

    Content type: Rapid communication

    Published on:

  24. Long non-coding RNAs (lncRNAs) possess significant regulatory functions in multiple biological and pathological processes, especially in cancer. Dysregulated lncRNAs in hepatocellular carcinoma (HCC) and their...

    Authors: Xueliang Zuo, Zhiqiang Chen, Wen Gao, Yao Zhang, Jinguo Wang, Junfeng Wang, Ming Cao, Juan Cai, Jindao Wu and Xuehao Wang

    Citation: Journal of Hematology & Oncology 2020 13:5

    Content type: Research

    Published on:

  26. The propensity of the activated neutrophils to form extracellular traps (NETs) is demonstrated in multiple inflammatory conditions. In this study, we investigated the roles of NETs in metastasis of hepatocellu...

    Authors: Lu-Yu Yang, Qin Luo, Lu Lu, Wen-Wei Zhu, Hao-Ting Sun, Ran Wei, Zhi-Fei Lin, Xiang-Yu Wang, Chao-Qun Wang, Ming Lu, Hu-Liang Jia, Jin-Hong Chen, Ju-Bo Zhang and Lun-Xiu Qin

    Citation: Journal of Hematology & Oncology 2020 13:3

    Content type: Research

    Published on:

  27. Clinically, the median survival in patients with metastatic renal cell carcinoma (RCC) was only 6–12 months and a 5-year survival rate of less than 20%. Therefore, an in-depth study of the molecular mechanisms...

    Authors: Qian Zhu, Ai-Lin Zhong, Hao Hu, Jing-Jing Zhao, De-Sheng Weng, Yan Tang, Qiu-Zhong Pan, Zi-Qi Zhou, Meng-Jia Song, Jie-Ying Yang, Jun-Yi He, Yuan Liu, Min Li, Wan-Ming Hu, Chao-Pin Yang, Tong Xiang…

    Citation: Journal of Hematology & Oncology 2020 13:2

    Content type: Research

    Published on:

  28. Axicabtagene ciloleucel (Axi-cel) is a CD-19 Chimeric Antigen Receptor T cell therapy approved for the treatment of relapsed/refractory diffuse large B cell lymphoma. We treated ten patients with DLBCL post-FD...

    Authors: Ahmed Abbasi, Stephen Peeke, Nishi Shah, Jennat Mustafa, Fariha Khatun, Amanda Lombardo, Michelly Abreu, Richard Elkind, Karen Fehn, Alyssa de Castro, Yanhua Wang, Olga Derman, Randin Nelson, Joan Uehlinger, Kira Gritsman, R. Alejandro Sica…

    Citation: Journal of Hematology & Oncology 2020 13:1

    Content type: Letter to the Editor

    Published on:

  29. In 2007, we initiated IMPACT, a precision medicine program for patients referred for participation in early-phase clinical trials. We assessed the correlation of factors, including genomically matched therapy,...

    Authors: Apostolia-Maria Tsimberidou, David S. Hong, Jennifer J. Wheler, Gerald S. Falchook, Filip Janku, Aung Naing, Siqing Fu, Sarina Piha-Paul, Carrie Cartwright, Russell R. Broaddus, Graciela M. Nogueras Gonzalez, Patrick Hwu and Razelle Kurzrock

    Citation: Journal of Hematology & Oncology 2019 12:145

    Content type: Research

    Published on:

  30. Signaling pathways critical for embryonic development re-emerge in adult pancreas during tumorigenesis. Aspartate β-hydroxylase (ASPH) drives embryonic cell motility/invasion in pancreatic development/differen...

    Authors: Kosuke Ogawa, Qiushi Lin, Le Li, Xuewei Bai, Xuesong Chen, Hua Chen, Rui Kong, Yongwei Wang, Hong Zhu, Fuliang He, Qinggang Xu, Lianxin Liu, Min Li, Songhua Zhang, Katsuya Nagaoka, Rolf Carlson…

    Citation: Journal of Hematology & Oncology 2019 12:144

    Content type: Research

    Published on:

  31. The original article [1] contains several errors.

    Authors: Kai Zhao, Yuxin Zhou, Chen Qiao, Ting Ni, Zhiyu Li, Xiaotang Wang, Qinglong Guo, Na Lu and Libin Wei

    Citation: Journal of Hematology & Oncology 2019 12:143

    Content type: Correction

    Published on:

    The original article was published in Journal of Hematology & Oncology 2015 8:41

  32. Cancer heterogeneity is regarded as the main reason for the failure of conventional cancer therapy. The ability to reconstruct intra- and interpatient heterogeneity in cancer models is crucial for understandin...

    Authors: Han Fan, Utkan Demirci and Pu Chen

    Citation: Journal of Hematology & Oncology 2019 12:142

    Content type: Review

    Published on:

  33. Chimeric antigen receptor (CAR) T cell therapy has been successful in treating B cell malignancies in clinical trials; however, fewer studies have evaluated CAR T cell therapy for the treatment of T cell malig...

    Authors: Lauren C. Fleischer, H. Trent Spencer and Sunil S. Raikar

    Citation: Journal of Hematology & Oncology 2019 12:141

    Content type: Review

    Published on:

  34. Statistical data on the incidence, mortality, and burden of breast cancer and the relevant risk factors are valuable for policy-making. We aimed to estimate breast cancer incidence, deaths, and disability-adju...

    Authors: Na Li, Yujiao Deng, Linghui Zhou, Tian Tian, Si Yang, Ying Wu, Yi Zheng, Zhen Zhai, Qian Hao, Dingli Song, Dai Zhang, Huafeng Kang and Zhijun Dai

    Citation: Journal of Hematology & Oncology 2019 12:140

    Content type: Research

    Published on:

  35. Adoptive T cell therapy has achieved dramatic success in a clinic, and the Food and Drug Administration approved two chimeric antigen receptor-engineered T cell (CAR-T) therapies that target hematological canc...

    Authors: Qinghua He, Xianhan Jiang, Xinke Zhou and Jinsheng Weng

    Citation: Journal of Hematology & Oncology 2019 12:139

    Content type: Review

    Published on:

  36. Endothelial-to-mesenchymal transition (EndoMT) can provide a source of cancer-associated fibroblasts which contribute to desmoplasia of many malignancies including pancreatic ductal adenocarcinoma (PDAC). We i...

    Authors: Chi-Shuan Fan, Li-Li Chen, Tsu-An Hsu, Chia-Chi Chen, Kee Voon Chua, Chung-Pin Li and Tze-Sing Huang

    Citation: Journal of Hematology & Oncology 2019 12:138

    Content type: Research

    Published on:

  39. METTL3 is an RNA methyltransferase that mediates m6A modification and is implicated in mRNA biogenesis, decay, and translation. However, the biomechanism through which METTL3 regulates MALAT1-miR-1914-3p-YAP axis...

    Authors: Dan Jin, Jiwei Guo, Yan Wu, Jing Du, Lijuan Yang, Xiaohong Wang, Weihua Di, Baoguang Hu, Jiajia An, Lingqun Kong, Lei Pan and Guoming Su

    Citation: Journal of Hematology & Oncology 2019 12:135

    Content type: Research

    Published on:

  42. Src, an oncoprotein that drives progression of head and neck squamous cell carcinoma (HNSCC), is commonly hyperactivated in this disease. Unfortunately, the clinical benefit of targeting Src is significantly d...

    Authors: Liwei Lang, Chloe Shay, Xiangdong Zhao, Yuanping Xiong, Xuli Wang and Yong Teng

    Citation: Journal of Hematology & Oncology 2019 12:132

    Content type: Research

    Published on:

  43. BCR-ABL1 kinase domain (KD) mutation status is considered to be an important element of clinical decision algorithms for chronic myeloid leukemia (CML) patients who do not achieve an optimal response to tyrosine ...

    Authors: Simona Soverini, Elisabetta Abruzzese, Monica Bocchia, Massimiliano Bonifacio, Sara Galimberti, Antonella Gozzini, Alessandra Iurlo, Luigiana Luciano, Patrizia Pregno, Gianantonio Rosti, Giuseppe Saglio, Fabio Stagno, Mario Tiribelli, Paolo Vigneri, Giovanni Barosi and Massimo Breccia

    Citation: Journal of Hematology & Oncology 2019 12:131

    Content type: Review

    Published on:

  44. Treatment outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC) remain dismal. There are unmet needs for understanding the biologic basis of this malignancy using novel next-generation se...

    Authors: Hitendra Patel, Ryosuke Okamura, Paul Fanta, Charmi Patel, Richard B. Lanman, Victoria M. Raymond, Shumei Kato and Razelle Kurzrock

    Citation: Journal of Hematology & Oncology 2019 12:130

    Content type: Short report

    Published on:

  45. Histone demethylase LSD1 plays key roles during carcinogenesis, targeting LSD1 is becoming an emerging option for the treatment of cancers. Numerous LSD1 inhibitors have been reported to date, some of them suc...

    Authors: Yuan Fang, Guochao Liao and Bin Yu

    Citation: Journal of Hematology & Oncology 2019 12:129

    Content type: Review

    Published on:

  47. Asparagine-linked (N-linked) glycosylation is ubiquitous and can stabilize immune inhibitory PD-1 protein. Reducing N-linked glycosylation of PD-1 may decrease PD-1 expression and relieve its inhibitory effects o...

    Authors: Xiaojuan Shi, Daiqun Zhang, Feng Li, Zhen Zhang, Shumin Wang, Yujing Xuan, Yu Ping and Yi Zhang

    Citation: Journal of Hematology & Oncology 2019 12:127

    Content type: Letter to the Editor

    Published on:

  48. Immunotherapy has become an emerging strategy for the treatment of cancer. Immunotherapeutic drugs have been increasing for clinical treatment. Despite significant advances in immunotherapy, the clinical appli...

    Authors: Zhongwei Zhao, Liyun Zheng, Weiqian Chen, Wei Weng, Jingjing Song and Jiansong Ji

    Citation: Journal of Hematology & Oncology 2019 12:126

    Content type: Review

    Published on:

  49. Immunotherapy is a currently popular treatment strategy for cancer patients. Although recent developments in cancer immunotherapy have had significant clinical impact, only a subset of patients exhibits clinic...

    Authors: Li Yang, Aitian Li, Qingyang Lei and Yi Zhang

    Citation: Journal of Hematology & Oncology 2019 12:125

    Content type: Review

    Published on:

  50. Human pancreatic ductal adenocarcinoma (PDAC) responds poorly to immune checkpoint inhibitor (ICPi). While the mechanism is not completely clear, it has been recognized that tumor microenvironment (TME) plays ...

    Authors: Yu Pan, Fengchun Lu, Qinglin Fei, Xingxing Yu, Ping Xiong, Xunbin Yu, Yuan Dang, Zelin Hou, Wenji Lin, Xianchao Lin, Zheyang Zhang, Minggui Pan and Heguang Huang

    Citation: Journal of Hematology & Oncology 2019 12:124

    Content type: Research

    Published on:

JHO logo
Submit manuscript

Follow

Annual Journal Metrics

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Advertisement

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us